• EDAP Reports Fourth Quarter 2020 Results and Provides Operational Update

    Source: Nasdaq GlobeNewswire / 30 Mar 2021 16:35:00   America/New_York

    • Generated record fourth quarter revenue of EUR 15.4 million (USD 18.3 million), an increase of 28% year-over-year; HIFU revenue up 51% year-over-year
    • Generated €41.7 million revenue and profitable operating result for the full year 2020.
    • Completed sales to renowned healthcare institutions, such as University of California, San Francisco Medical Center and Cleveland Clinic
    • Strong and increased cash position of EUR 24.7 million (USD 30.2 million) as of December 31, 2020
    • Company to host a conference call tomorrow, March 31, at 8:30 am ET

    LYON, France, March 30, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter of 2020 and provided an update on strategic and operational developments. 

    Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: “During the fourth quarter and full year 2020, we made great strides toward our mission of becoming a leader in the field of high intensity focused ultrasound. We delivered sequential revenue growth each quarter of the year notwithstanding the impact of the pandemic. We ended on a high note by delivering 28% year-over-year total revenue growth and 51% year-over-year HIFU revenue growth during the quarter, and in the process welcomed University of California, San Francisco Medical Center (UCSF) and Cleveland Clinic to our growing roster of highly regarded Focal One customers. This success was driven not only by the growing recognition of Focal One as a new treatment paradigm in the non-invasive ablation of cancerous prostate tissue, but also our strategic licensing agreement with Exact Imaging, and its lead product Exact Vu, which provides us with a comprehensive urology solution.

    “Notably, we achieved all of this while delivering operating profitability for both the fourth quarter and full year and ended the year with an increased cash position of EUR 24.7 million. I believe we are well positioned to continue this momentum through 2021.”

    Fourth Quarter 2020 Results

    Total revenue for the fourth quarter 2020 was EUR 15.4 million (USD 18.3 million), an increase of 28.2% compared to total revenue of EUR 12.0 million (USD 13.3 million) for the same period in 2019.

    Total revenue in the HIFU business for the fourth quarter 2020 was EUR 4.4 million (USD 5.2 million), a 50.8% increase compared to EUR 2.9 million (USD 3.2 million) for the fourth quarter of 2019.

    Total revenue in the LITHO business for the fourth quarter 2020 was EUR 4.6 million (USD 5.5 million), a 10.6% increase compared to EUR 4.2 million (USD 4.6 million) for the fourth quarter of 2019.

    Total revenue in the Distribution business for the fourth quarter 2020 was EUR 6.4 million (USD 7.6 million), a 29.7% increase compared to EUR 4.9 million (USD 5.5 million) for the fourth quarter of 2019.

    Gross profit for the fourth quarter 2020 was EUR 7.0 million (USD 8.4 million), compared to EUR 5.1 million (USD 5.7 million) for the year-ago period. Gross profit margin on net sales was 45.8% in the fourth quarter of 2020, compared to 43.0% in the year-ago period. The increase in gross profit year-over-year was due to higher HIFU equipment sales.

    Operating expenses were EUR 5.3 million (USD 6.3 million) for the fourth quarter of 2020, compared to EUR 5.1 million (USD 5.6 million) for the same period in 2019.

    Operating profit for the fourth quarter of 2020 was EUR 1.7 million (USD 2.1 million), compared to an operating profit of EUR 0.08 million (USD 0.09 million) in the fourth quarter of 2019.

    Net income for the fourth quarter of 2020 was EUR 0.8 million (USD 0.9 million), or EUR 0.03 per diluted share, as compared to a net loss of EUR 1.0 million (USD 1.1 million), or EUR (0.03) per diluted share in the year-ago period.

    Full Year 2020 Results

    Total revenue for the full year 2020 was EUR 41.7 million (USD 47.8 million), a decrease of 7% compared to total revenue of EUR 44.9 million (USD 50.2 million) for the full year 2019. Full year revenue reflects the impact of the ongoing COVID-19 pandemic on the company’s activities.

    Total revenue in the HIFU business for the full year 2020 was EUR 11.4 million (USD 13.1 million), a 19% decrease compared to EUR 14.1 million (USD 15.8 million) for the full year 2019.

    Total revenue in the LITHO business for the full year 2020 was EUR 12.9 million (USD 14.8 million), a 9.2% decrease compared to 14.2 million (USD 15.9 million) for the full year 2019.

    Total revenue in the Distribution business for the full year 2020 was EUR 17.3 million (USD 19.9 million), a 4.6% increase compared to EUR 16.6 million (USD 18.5 million) for the full year 2019.

    Gross profit for the full year 2020 was EUR 18.4 million (USD 21.1 million), compared to EUR 21.0 million (USD 23.5 million) for the full year 2019. Gross profit margin on net sales was 44.1% for the full year 2020, compared to 46.8% in the prior year. The decline in gross profit year-over-year was due in part to lower sales in the HIFU business driven by COVID-19.

    Operating expenses were EUR 18.1 million (USD 20.8 million) for the full year 2020, compared to EUR 18.8 million (USD 21.0 million) for the full year 2019.

    Operating profit for the full year 2020 was EUR 0.3 million (USD 0.3 million), compared to an operating profit of EUR 2.2 million (USD 2.5 million) for the full year 2019.

    Net loss for the full year 2020 was EUR 1.7 million (USD 2.0 million), or EUR (0.06) per diluted share, as compared to a net income of EUR 1.5 million (USD 1.7 million), or EUR 0.05 per diluted share in the prior year.

    As of December 31, 2020, the Company recorded a strong cash position of EUR 24.7 million (USD 30.2 million).

    Conference Call

    An accompanying conference call and webcast will be conducted by management to review the results. The call will be held at 8:30am EDT tomorrow, March 31, 2021. Please refer to the information below for conference call dial-in information and webcast registration.

    Conference Call & Webcast
    Wednesday, March 31, 2021 @ 8:30am Eastern Time
    Domestic:                877-451-6152
    International:                201-389-0879
    Passcode:                13717550
    Webcast:                http://public.viavid.com/index.php?id=143913

    Following the live call, a replay will be available on the Company's website, www.edap-tms.com under "Investors Information."

    About EDAP TMS SA

    A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

    Forward-Looking Statements

    In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as the length and severity of the COVID-19 pandemic, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

    Company Contact
    Blandine Confort
    Investor Relations / Legal Affairs
    EDAP TMS SA
    +33 4 72 15 31 50
    bconfort@edap-tms.com

    Investor Contact
    Jeremy Feffer
    LifeSci Advisors, LLC
    212-915-2568
    jeremy@lifesciadvisors.com

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Amounts in thousands of Euros and U.S. Dollars, except per share data)


          		Three Months Ended:   Three Months Ended:
      Dec. 31,
    2020
    Euros     		 

          		Dec. 31,
    2019
    Euros     		  Dec. 31,
    2020
    $US     		  Dec. 31,
    2019
    $US     		   
    Sales of medical equipment 11,439   7,972   13,661   8,876    
    Net Sales of RPP and Leases 1,336   1,719   1,596   1,914    
    Sales of spare parts, supplies and Services 2,587   2,259   3,089   2,515    
    TOTAL NET SALES 15,363   11,950   18,346   13,305    
    Other revenues 1   37   2   42    
    TOTAL REVENUES 15,364   11,988   18,348   13,346    
    Cost of sales (8,335)   (6,848)   (9,953)   (7,624)    
    GROSS PROFIT 7,029   5,139   8,394   5,722    
    Research & development expenses (1,439)   (844)   (1,718)   (939)    
    S, G & A expenses (3,871)   (4,216)   (4,622)   (4,694)    
    Total operating expenses (5,310)   (5,060)   (6,341)   (5,633)    
    OPERATING PROFIT (LOSS) 1,720   79   2,053   88    
    Interest (expense) income, net (46)   (43)   (55)   (48)    
    Currency exchange gains (loss), net (728)   (652)   (869)   (726)    
    INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST 945   (616)   1,129   (685)    
    Income tax (expense) credit (165)   (362)   (197)   (403)    
    NET INCOME (LOSS)

          		780   (978)   932   (1,088)    
    Earning per share – Basic 0.03   (0.03)   0.03   (0.04)    
    Average number of shares used in computation of EPS 29,164,983   29,047,028   29,164,983   29,047,028    
    Earning per share – Diluted 0.03   (0.03)   0.03   (0.04)    
    Average number of shares used in computation of EPS for positive net income

          		30,222,258   29,047,028   30,222,258   29,047,028    

    NOTE: Translated for convenience of the reader to U.S. dollars at the 2020 average three months’ noon buying rate of 1 Euro = 1.1942 USD, and 2019 average three months noon buying rate of 1 Euro = 1.1133 USD

    EDAP TMS S.A.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Amounts in thousands of Euros and U.S. Dollars, except per share data)

      Twelve Months Ended:   Twelve Months Ended:
      Dec. 31,
    2020
    Euros     		 

          		Dec. 31,
    2019
    Euros     		  Dec. 31,
    2020
    $US     		  Dec. 31,
    2019
    $US     		   
    Sales of medical equipment 27,523   30,111   31,581   33,678    
    Net Sales of RPP and Leases 4,745   5,747   5,445   6,428    
    Sales of spare parts, supplies and Services 9,382   9,001   10,765   10,067    
    TOTAL NET SALES 41,649   44,859   47,791   50,173    
    Other revenues 12   52   14   59    
    TOTAL REVENUES 41,662   44,912   47,805   50,231    
    Cost of sales (23,283)   (23,909)   (26,716)   (26,741)    
    GROSS PROFIT 18,379   21,002   21,089   23,490    
    Research & development expenses (4,496)   (3,728)   (5,159)   (4,169)    
    S, G & A expenses (13,614)   (15,074)   (15,621)   (16,859)    
    Total operating expenses (18,110)   (18,802)   (20,780)   (21,029)    
    OPERATING PROFIT (LOSS) 269   2,201   309   2,461    
    Interest (expense) income, net (98)   (146)   (112)   (163)    
    Currency exchange gains (loss), net (1,359)   136   (1,559)   152    
    Other income, net -   -   (1)   -    
    INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (1,188)   2,191   (1,363)   2,451    
    Income tax (expense) credit (516)   (679)   (592)   (760)    
    NET INCOME (LOSS)

          		(1,704)   1,512   (1,955)   1,691    
    Earning per share – Basic (0.06)   0.05   (0.07)   0.06    
    Average number of shares used in computation of EPS 29,148,108   29,016,118   29,148,108   29,016,118    
    Earning per share – Diluted (0.06)   0.05   (0.07)   0.06    
    Average number of shares used in computation of EPS for positive net income

          		29,148,108   29,615,466   29,148,108   29,615,466    

    NOTE: Translated for convenience of the reader to U.S. dollars at the 2020 average twelve months’ noon buying rate of 1 Euro = 1.1474 USD, and 2019 average twelve months noon buying rate of 1 Euro = 1.1184 USD 

    EDAP TMS S.A.
    UNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS
    (Amounts in thousands of Euros and U.S. Dollars)

      Dec. 31,
    2020
    Euros     		 

          		Sept. 30,
    2020
    Euros     		  Dec. 31,
    2020
    $US     		  Sept. 30,
    2020
    $US
    Cash, cash equivalents and short-term treasury investments 24,696   19,929   30,201   23,364
    Account receivables, net 12,339   11,572   15,090   13,567
    Inventory 7,989   9,455   9,771   11,084
    Other current assets 369   604   451   708
    TOTAL CURRENT ASSETS 45,393   41,560   55,513   48,722
    Property, plant and equipment, net 5,599   5,928   6,847   6,950
    Goodwill 2,412   2,412   2,949   2,827
    Other non-current assets 1,790   1,739   2,189   2,039
    TOTAL ASSETS 55,193   51,639   67,498   60,538
    Accounts payable & other accrued liabilities 10,485   9,122   12,823   10,694
    Deferred revenues, current portion 2,701   2,695   3,304   3,160
    Short term borrowing 2,638   1,459   3,227   1,711
    Other current liabilities 5,679   5,825   6,945   6,829
    TOTAL CURRENT LIABILITIES 21,504   19,102   26,298   22,394
    Obligations under operating and finance leases non-current 1,653   1,724   2,022   2,021
    Long term debt, non-current 1,143   1,219   1,397   1,429
    Deferred revenues, non-current 926   821   1,132   963
    Other long term liabilities 3,720   3,626   4,549   4,251
    TOTAL LIABILITIES 28,945   26,493   35,399   31,059
    TOTAL SHAREHOLDERS’EQUITY 26,248   25,146   32,099   29,480
    TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY 55,193   51,639   67,498   60,538

    NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.2229 USD on December 31, 2020 and at the noon buying rate of 1 Euro = 1.1723 USD, on September 30, 2020

    EDAP TMS S.A.
    UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (Amounts in thousands of Euros)

      Dec. 31, 2020
    Euros     		  Sept. 30, 2020
    Euros     		  Dec. 31, 2020
    $US     		  Sept. 30 2020
    $US
    NET INCOME (LOSS) (1,704)   (2,484)   (1,955)   (2,812)
    Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) 3,790   2,211   4,349   2,503
    OPERATING CASH FLOW 2,087   (273)   2,394   (309)
    Increase/Decrease in operating assets and liabilities (110)   (1,735)   (126)   (1,964)
    NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES 1,977   (2,008)   2,269   (2,273)
    Short term investments(2) -   (1,708)   -   (1,933)
    Additions to capitalized assets produced by the company and other capital expenditures (2,011)   (1,508)   (2,307)   (1,707)
    NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES (2,011)   (3,216)   (2,307)   (3,640)
    NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES 3,201   2,248   3,673   2,544
    NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS 642   312   3,118   1,281
    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 3,810   (2,665)   6,752   (2,088)

    (1) including Share based compensation expenses for 160 thousands of Euros at the end of December 2020, and 134 thousands of Euros at the end of September 2020

    (2) Short term investments are comprised of money market funds

    NOTE: Translated for convenience of the reader to U.S. dollars at the 2020 average twelve months’ noon buying rate of 1 Euro = 1.1474 and 2020 average nine months’ noon buying rate of 1 Euro = 1.1319 USD.

            

    EDAP TMS S.A.
    UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
    TWELVE MONTHS ENDED DECEMBER 31, 2020
    (Amounts in thousands of Euros)

       

    HIFU
    Division     		   

    ESWL
    Division     		   

    Distribution
    Division     		   

    Reconciling
    Items     		   

    Total After Consolidation     		   
     

    Sales of goods     		 

    6,000     		   

    6,248     		   

    15,274     		       

    27,523     		   
    Sales of RPPs & Leases 3,594   927   224       4,745    
    Sales of spare parts & services 1,831   5,707   1,844       9,382    
    TOTAL NET SALES

          		11,425   12,882   17,342       41,649    
    Other revenues

          		12   0   0       12    
    TOTAL REVENUES 11,438   12,882   17,342       41,662    
    GROSS PROFIT
    (% of Total Revenues)     		6,293 55.0 % 5,649 43.9% 6,436 37.1%     18,379 44.1%
     

    Research & Development     		 

    (2,583)     		  (1,555)   (358)       (4,496)    
    Total SG&A plus depreciation (4,156)   (3,016)   (4,976)   (1,465)   (13,614)    
     

    OPERATING PROFIT (LOSS)     		 

    (445)     		   

    1,078     		   

    1,102     		   

    (1,465)     		   

    269     		   

     

    Attachment


    Primary Logo

Share on,